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ABSTRACT: Background: Juvenile forms of parkinson-
ism are rare conditions with onset of bradykinesia, tremor
and rigidity before the age of 21 years. These atypical
presentations commonly have a genetic aetiology,
highlighting important insights into underlying pathophysiol-
ogy. Genetic defects may affect key proteins of the
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endocytic pathway and clathrin-mediated endocytosis
(CME), as in DNAJC6-related juvenile parkinsonism.
Objective: To report on a new patient cohort with
juvenile-onset DNAJC6 parkinsonism-dystonia and
determine the functional consequences on auxilin and
dopamine homeostasis.
Methods: Twenty-five children with juvenile parkinsonism
were identified from a research cohort of patients with
undiagnosed pediatric movement disorders. Molecular
genetic investigations included autozygosity mapping
studies and whole-exome sequencing. Patient fibroblasts
and CSF were analyzed for auxilin, cyclin G–associated
kinase and synaptic proteins.
Results: We identified 6 patients harboring previously
unreported, homozygous nonsense DNAJC6 mutations.
All presented with neurodevelopmental delay in infancy,
progressive parkinsonism, and neurological regression in
childhood. 123I-FP-CIT SPECT (DaTScan) was performed
in 3 patients and demonstrated reduced or absent tracer
uptake in the basal ganglia. CSF neurotransmitter analy-
sis revealed an isolated reduction of homovanillic acid.
Auxilin levels were significantly reduced in both patient
fibroblasts and CSF. Cyclin G–associated kinase levels in
CSF were significantly increased, whereas a number of
presynaptic dopaminergic proteins were reduced.
Conclusions: DNAJC6 is an emerging cause of recessive
juvenile parkinsonism-dystonia. DNAJC6 encodes the
cochaperone protein auxilin, involved in CME of synaptic
vesicles. The observed dopamine dyshomeostasis in
patients is likely to be multifactorial, secondary to auxilin
deficiency and/or neurodegeneration. Increased patient
CSF cyclin G–associated kinase, in tandem with reduced
auxilin levels, suggests a possible compensatory role of
cyclin G–associated kinase, as observed in the auxilin
knockout mouse. DNAJC6 parkinsonism-dystonia should
be considered as a differential diagnosis for pediatric neu-
rotransmitter disorders associated with low homovanillic
acid levels. Future research in elucidating disease patho-
genesis will aid the development of better treatments for
this pharmacoresistant disorder. © 2020 The Authors.
Movement Disorders published by Wiley Periodicals, Inc.
on behalf of International Parkinson and Movement Disor-
der Society.
Key Words: auxilin; DNAJC6; dopamine; dystonia;
parkinsonism
Classical Parkinson’s disease (PD) is an age-related neu-
rodegenerative disorder, mainly affecting adults aged
>50 years. Patients typically present with resting tremor,
bradykinesia, rigidity, and postural instability. To date, a
number of early-onset genetic forms of PD (Parkin,
PINK1, and DJ-1)1-3 and complex parkinsonism syn-
dromes (ATP13A2, PLA2G6, FBXO7, SLC6A3,
SLC39A14, and PANK2) have been described.4-9 Impor-
tantly, the study of such monogenic forms of disease have
provided significant insight into the pathogenic mecha-
nisms underlying sporadic PD.10 More recently, two
genes, namely SYNJ111 andDNAJC6,12-14 encoding pro-
teins involved in postendocytotic recycling of synaptic ves-
icles, have been identified in early-onset parkinsonism.
In this study, we report on 6 children from three families,
presenting with juvenile parkinsonism-dystonia associated
with novel, biallelic DNAJC6 mutations. We delineate
their clinical phenotype, neuroimaging features (including
123I-FP-CIT single-photon emission computed tomogra-
phy [SPECT; DaTScan]) and pattern of cerebrospinal fluid
(CSF) neurotransmitter metabolites. Furthermore, we uti-
lized patient fibroblasts and CSF to investigate secondary




A cohort of 232 children with undiagnosed movement
disorders were recruited for research between 2012 and
2016 at UCL Great Ormond Street–Institute of Child
Health (London, UK). A subgroup of 25 patients were iden-
tified with juvenile parkinsonism, defined as onset of
bradykinesia before 21 years of age, and at least one of the
following signs: resting tremor, rigidity, and postural insta-
bility. All patients had detailed clinical assessment, under-
taken by a movement disorder specialist. Review of (1) the
clinical history, (2) features on neuroimaging, and (3) video
recordings of themovement disorder at different time points
was undertaken. Written informed consent was obtained
from participating families, and the study was approved by
the local ethics committees (Reference 13/LO/0168).
Diagnostic CSF Neurotransmitter Analysis:
In order to rule out a primary neurotransmitter disorder,
where possible, patients had a routine diagnostic lumbar
puncture for CSF neurotransmitter analysis. Using stan-
dardized protocols,15 CSF samples were collected, snap
frozen in liquid nitrogen, and stored at –80C. Analysis
was undertaken using high-pressure liquid chromatogra-
phy (HPLC) with electrochemical detection and reversed-
phase column.15 Seven anonymized control pediatric CSF
samples (with normal CSF neurotransmitter profiles) were
obtained from the Neurometabolic Laboratory (National
Hospital for Neurology and Neurosurgery, London, UK).
All samples were processed and stored in accordance with
the UKRoyal College of Pathologists guidelines.
Molecular Genetic Investigation:
From the subgroup of 25 patients with juvenile parkin-
sonism (16 singletons and 9 familial cases from 3 kin-
dreds), we prioritized two consanguineous families
1358 Movement Disorders, Vol. 35, No. 8, 2020
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(Family A, 3 affected children; Family B, 2 affected chil-
dren) for initial analysis. These families were investigated
using an autozygosity mapping approach, given that the
affected children were phenotypically similar and both
families originated from the same region in Pakistan.
Single-nucleotide polymorphism (SNP) genotyping was
performed as previously described.16 In addition, whole-
exome sequencing (WES) was performed for 2 children
(A:III-1 and B:IV-2) by UCLGenomics (averageWES cov-
erage as previously reported17), with an averageDNAJC6
coverage of 30×, with minimum coverage 10× for 82% of
the gene. WES data were probed for putative disease-
causing DNAJC6 mutations in the remaining 20 cases
(16 sporadic patients, 4 familial cases from a single kin-
dred). This was undertaken through UCL Genomics
(8 patients) and Wellcome Trust Sanger Institute
(12 patients) within theWellcome Trust UK10KRare Dis-
eases project, as previously reported.18 For patients where
DNAJC6 mutations were identified, whole-exome data
were also probed for other genes associated with early-
onset dystonia-parkinsonism (Table 1).
Direct Sanger Sequencing
Sanger sequencing was used to confirm variants
identified on WES and to establish familial segregation.
A genomic DNAJC6 sequence (Ensembl transcript:
ENST00000371069; NCBI reference sequence:
NM_001256864) was utilized to design primers, using
Primer3 software (http://bioinfo.ut.ee/primer3/). Primers
and polymerase chain reaction (PCR) amplification
conditions are available on request. PCR products were
cleaned up with MicroCLEAN (Web Scientific) and
directly sequenced using Big Dye Terminator Cycle
Sequencing System (Applied Biosystems Inc., Foster
City, CA). Sequencing reactions were run on an ABI
PRISM 3730 DNA Analyzer (Applied Biosystems Inc.)
and analyzed with Chromas (http://www.technelysium.
com.au/chromas.html).
Fibroblast and CSF Immunoblotting:
Methods to assess protein expression in patient fibro-
blasts were as previously reported.17 In brief, primary
fibroblast lines were cultured from skin biopsies taken
from Patients A-III:1 and B-IV:4 (c.766C>T; p.R256*)
and 2 age-matched healthy donor controls. Antibodies for
auxilin and GAK (gift from Professor Green, National
Institutes of Health, Washington, DC) and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) horseradish perox-
idase (HRP) conjugate (Cell Signaling Technology, Inc.,
Danvers,MA)were used.
Patients A-III:1, A-III:4, and B-IV:4 underwent lumbar
puncture for diagnostic CSF neurotransmitter analysis,
and three CSF aliquots were snap frozen and stored at
−80C. Seven age-matched control CSF samples were
identified, from subjects without movement disorders on
no medication. Patient and control CSF samples were
immunoblotted for auxilin, GAK, and dopaminergic pro-
teins as described previously.19 CSF protein was probed
with the following antibodies: auxilin, GAK, tyrosine
hydroxylase (MilliporeSigma, Burlington, MA), dopa-
mine receptor 2 (MilliporeSigma), dopamine transporter
(MilliporeSigma), vesicular monoamine transporter
2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), and
transferrin (Santa Cruz Biotechnology, Inc) as the loading
control. Relative protein levels were quantified using
ImageJ software (National Institutes of Health, Bethesda,
MD) and normalized to the loading control and the mean
percentage of optical densitometry of three replicates ana-
lyzedwith standard error of the mean.
Statistical Analysis
Statistical analysis was performed using Prism soft-
ware (version 8; GraphPad Software Inc., La Jolla,
CA), with data tested for Gaussian distribution and
compared by the Student t test.
Data Availability Statement:
All clinical and experimental data relevant to this study
are contained within the article. For Families A, B, and C,
there is no ethical approval in place for deposition of
whole-exome sequencing genomic data into a public reposi-
tory. Genomic data from UK10K are available at the EGA
European Genomen Phenome Archive (https://www.ebi.ac.
uk/ega/home), EGAS00001000128(UK10K RARE FIND).
Details of statistical analysis can be shared upon request.
Results
Patient Cohort
A total of 232 children were referred with
undiagnosed movement disorders for genetic research
(Fig. 1A). Of these, 25 children (10.7%) had juvenile
parkinsonism, 16 females and 9 males with a current
median age of 14 years (range, 4–28). Fourteen of
25 had additional neurological features, including dys-
tonia (14 patients), developmental delay/learning diffi-
culties (14 patients), and seizures (4 patients; Fig. 1B).
Molecular Genetic Investigations
Families A and B (Fig. 1A) were prioritized for auto-
zygosity mapping studies. SNP genotyping revealed a
4.33-Mb region of common homozygosity in both families
on chromosome 1, between rs640407 (64,267,606 base
pairs [bp]) and rs2566784 (68,602,735 bp; Fig. 2A,B). This
region showed a common haplotype in all affected children
whereas unaffected siblings had a different haplotype. It was
therefore considered to be the likely disease locus (Fig. 2B).
WES performed in Patients A-III:1 and B-IV:2 revealed
23,365 and 23,549 variants, respectively. Given familial
1360 Movement Disorders, Vol. 35, No. 8, 2020
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FIG. 1. Juvenile parkinsonism cohort: clinical features and molecular genetic investigation. (A) Flowchart demonstrating the pathway of
molecular genetic investigations in a subcohort of 25 children with juvenile parkinsonism. (B) Clinical characteristics of 20 children from
17 families. Early infancy <3 months; infancy 3 to 12 months; toddler 12 to 24 months; childhood 2 to 13 years; adolescence 13 to
18 years. *Consanguineous family. M, male; F, female; N, normal; NP, not performed; NR, not reported. [Color figure can be viewed at
wileyonlinelibrary.com]
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FIG. 2. Molecular genetic investigations and DaTSCAN imaging. (A) Family A and B SNP array results showing homozygous regions detected. For each chro-
mosome, the start and end point is specified using the Reference SNP Cluster ID (rs number) and physical position. (B) Homozygous SNPs are represented in
light blue (AA) and dark blue (BB), heterozygous SNPs in red (AB), and “no calls” in white. (C) Sanger Sequencing confirms a homozygousDNAJC6mutation,
c.766C > T (p.R256*), in all affected children of Family A (A-III:1, A-III:4, and A-III:5) and Family B (B-IV:2, B-IV:4). Parents are heterozygous carriers.
(D) I-123-DaTSCAN™ with SPECT imaging in a control subject, Patient A-III:1 (19 years 3 months), Patient A-III:4 (11 years 4 months), and Patient B-IV:4
(17 years). In Patients A-III:1 andB-IV:4, DaTSCAN findings indicate virtually complete absence of tracer uptake in the basal ganglia, with very high background
activity, suggesting loss of presynaptic dopaminergic terminals, whereas Patient A-III:4 showed significantly reduced, albeit still visible, uptake in the head of
caudate (left better than right, white arrows). [Color figure can be viewed at wileyonlinelibrary.com]
1362 Movement Disorders, Vol. 35, No. 8, 2020
N G E T A L
consanguinity and the autozygosity mapping results,
targeted analysis for recessive pathogenic variants within
the putative disease locus on chromosome 1 was under-
taken. A single homozygous nonsense variant c.766C>T
(p.R256*) in DNAJC6 (Chr1, 65,248,219–65,415,869)
was identified both in A-III:1 and B-IV:2 on WES, located
within the common region of homozygosity. No other
pathogenic changes in previously reported genes causing
juvenile parkinsonism-dystonia phenotypes were identified
from the WES data. Direct Sanger sequencing confirmed
the homozygous c.766C>T mutation in all 5 affected
patients, and familial segregation studies revealed that all
parents were obligate carriers in both kindreds, with unaf-
fected siblings eitherwild type or heterozygous for the iden-
tified variant (Fig. 2C). WES/whole-genome sequencing
data for the remainder of the parkinsonism-dystonia
cohort (n = 20) was interrogated for DNAJC6 mutations.
This led to the identification of a homozygous nonsense
variant (c.2416C>T) in a sixth unrelated patient (Patient
C), whichwas confirmed on Sanger sequencing.
Delineation of the Clinical Phenotype of
DNAJC6 Patients
Family A (3 Affected Patients)
Patients A-III:1, A-III:4, and A-III:5 are 3 affected chil-
dren born to first-cousin parents, currently 20, 12, and
10 years old (Table 1). Two other brothers (A-III:2 and A-
III:3), aged 17 and 15 years, have mild learning difficulties
without evidence of a movement disorder. The paternal
grandfather was diagnosed with PD in his fifties.
All 3 children were born at term after an uneventful
antenatal period. Microcephaly was evident at birth
(head circumference: <0.4th centile), but nonprogressive
over time. All siblings had early neurodevelopmental
delay and moderate learning difficulties.
A-III:1 is the eldest daughter, aged 20 years. She pres-
ented at 10 years, with a 6-week history of feeding diffi-
culties, vomiting, and weight loss. Over time, she
developed fever, unsteady gait, facial asymmetry, left-
sided tremor, and generalized seizures and was diag-
nosed with an encephalitis of uncertain etiology. She
recovered from this acute illness, but subsequently had
progressive bradykinesia, with tremor and rigidity, and
loss of independent ambulation at 13 years, associated
with cognitive decline. She is now wheelchair depen-
dent, with generalised cogwheel-rigidity, severe
bradykinesia, multiple limb contractures and emotional
lability (Video 1). She also has severe gut dysmotility,
with recurrent vomiting, and required a gastrostomy
for deteriorating bulbar dysfunction. CSF neurotrans-
mitter analysis (age 11 years), while on levodopa ther-
apy, revealed an isolated low 5-hydroxyindoleacetic
acid (5-HIAA; Fig. 3A). At 12 years 11 months, when
off L-dopa, CSF HVA, and HVA:5-HIAA ratio were
low. Brain MRI showed evidence of right-sided atrophy
of the perisylvian region and right cerebellum by
19 years of age (Supporting Information Fig. S1). At
19 years, 123I-FP-CIT SPECT (DaTScan) showed absent
uptake in the basal ganglia when compared to normal
subjects (Fig. 2D). At this stage, while on L-dopa treat-
ment, her CSF HVA levels normalized (Fig. 3A). Her
condition is refractory to medical treatment, with no
clinical response to trihexyphenidyl, benzhexol, proc-
yclidine, clobazam, rotigotine, and apomorphine. L-
dopa has proven difficult to titrate because of marked
drug sensitivity. She experiences an improvement in
motor function and speech 30 minutes postdose, after
which she returns to the off state. L-dopa dosages >150
mg/d have resulted in drug-related dyskinesias.
Her two brothers (A-III:4 and A-III:5) presented with
fine motor difficulties at 8 years of age. They subse-
quently developed positional tremor, upper limb dys-
tonic posturing, hypophonia, hypomimia, bradykinesia,
cogwheel rigidity, and postural instability over 12months
(Videos 2 and 3). Like their sister, both have gastrointes-
tinal complications with sialorrhea, recurrent vomiting,
and feeding difficulties, necessitating gastrostomy inser-
tion. A-III:4 is currently 12 years old and suffers from
anxiety and perseveration. His CSF-HVA levels are at the
lower limit of normal, with a low HVA:5-HIAA
ratio <1.0 (Fig. 3A). MRI brain scan was normal.
123I-FP-CIT SPECT (DaTScan) at 11 years showed pro-
found reduction in tracer uptake in the basal ganglia
(Fig. 2D). Both boys responded to treatment with trans-
dermal rotigotine and oral trihexyphenidyl, but with
increasing doses, both experienced dyskinesias, necessi-
tating dose reduction.
Family B (2 Affected Patients)
Patients B-IV:2 and B-IV:4 are 2 affected girls, born to
first-cousin parents, and currently 28 and 19 years old.
Both were born uneventfully following a normal preg-
nancy, presenting with early feeding difficulties, hypoto-
nia, and delayed milestones by 6 months old. Both made
slow developmental progress, achieving independent
ambulation and spoken language by 3 years of age.
B-IV:2 presented at 9 years with generalized seizures
that stabilized with lamotrigine therapy. From 13 years
of age, motor and cognitive deterioration ensued, with
onset of parkinsonism and loss of speech and ambula-
tion. She experienced anxiety and recurrence of seizures.
She has severe antecollis, hypomimia, tremor, generalised
cogwheel rigidity, bradykinesia, and positive glabellar
tap (Video 4). MRI was normal until 18 years, after
which there was radiological evidence of mild generalized
atrophy. Several medications were tried without clinical
benefit, including L-dopa (maximum, 10 mg/kg/d),
selegiline, rotigotine, and trihexyphenidyl. The younger
sibling, B-IV:4, presented at 7 years with gait deteriora-
tion, bradykinesia, and cogwheel rigidity. She lost
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FIG. 3. CSF neurotransmitter analysis and patient fibroblast and CSF immunoblotting. (A) CSF neurotransmitter analysis. Age-related reference ranges indicated
in brackets after each value. Red: abnormal result. Gray: borderline result. Symbol (“#”) indicates reference range: 1KeithHyland, Robert A.H. Surtees, et al. Pediatr
Res 1993;34:10–14; 2Keith Hyland, Future Neurol 2006;1:593–603; 3Surtees R, Hyland K. BiochemMedMetab Biol 1990;44:192–199. (B) Scatterplot of CSFHVA
and 5-HIAA levels (nmol/L)measured by high performance liquid chromatography (patient = red shapes, control = black triangles).Medication at time ofCSF sam-
pling: A-III-1: co-careldopa, melatonin, glycopyronium; A-III-4: none; B-IV-4: L-dopa, pyridoxine; Control 1: none; Control 2: none. Immunoblot of auxilin and GAK
in patient fibroblasts (C) and CSF (D) compared to controls. (E) Immunoblot of patient CSF for TH, DAT, VMAT, and D2R protein levels measured compared to
controls. Graphs showmean protein percent optical density (OD) normalized to loading control in patients (red) and controls (black). LP, lumbar puncture; y, years;
m,months; 5-MTHF, 5-methyltetrahydrofolate; NP, not performed. [Color figure can be viewed at wileyonlinelibrary.com]
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independent ambulation and speech by 10 years (Video
5). She has developed dystonic posturing, bulbar dys-
function (necessitating gastrostomy), and a disrupted
sleep pattern. The MRI brain scan was initially normal,
but by 16 years showed subtle global cerebral atrophy
(particularly in the posterior regions) as well as cerebellar
atrophy (Supporting Information Fig. S2). 123I-FP-CIT
SPECT (DaTScan) at 17 years showed profound reduc-
tion in tracer uptake in the basal ganglia (Fig. 2D). CSF
HVA and HVA:5-HIAA ratio were reduced at ages 4 and
14 years. CSF-HIAA levels were reduced at age 4 years
(Fig. 3A). She showed an initial response to L-dopa, but
developed emotional lability at 5.5 mg/kg/d, leading to
drug withdrawal. There was no clinical improvement
observed with trihexyphenidyl or chloral hydrate. She
had a modest response to pramipexole, with improved
facial expression, reduced tremor, and increase in volun-
tary movements.
Family C
This 18-year-old girl is the third child of distantly related
Latin American parents, with 2 healthy siblings. She ini-
tially presented with neonatal feeding difficulties and
hypotonia. In infancy, she showed delay in attaining mile-
stones and developed seizures characterized by staring epi-
sodes with loss of tone. She walked independently from
2 years, but by 10 years of age her gait deteriorated, lead-
ing to frequent falls, postural instability, and losing the
ability to run.Over the next 4 years, she continued to dete-
riorate with worsening antecollis and bradykinesia (Video
6). She developed severe bulbar dysfunction with
sialorrhea, dysarthria, and, dysphagia, leading to consid-
erable weight loss. At 12 years, she developed generalized
tonic-clonic seizures and atypical absences, responsive to
lamotrigine and zonisamide therapy. MRI demonstrated
subtle generalized cerebral atrophy and CSF HVA was
low (Fig. 3A). Her movement disorder responded to L-
dopa, with improved tremor, gait, and a reduction in dro-
oling. A maximum of 200 mg/d was tolerated, but further
increases led to intolerable drug-induced dyskinesias.
After 4 months of treatment, she developed aggressive
behavior and received treatment with quetiapine. By
16 years, she became increasingly sensitive to L-dopa, with
peak-dose agitation, restlessness, and dyskinesia. Lower-
ing the dose improved side effects, and continued to pro-
vide motor benefit, although the effects wore off 2 to
3 hours after administration. On-off phenomena were
commonly reported, and in the off state, she was often
akinetic and rigid. Introduction of trihexyphenidyl
improved rigidity, but not immobility.
Patient CSF and Fibroblast Analysis
CSF HPLC analysis of the DNAJC6 patient cohort
showed reduction in CSF-HVA levels (P = 0.002) com-
pared to controls (but not 5-HIAA levels) in 3 patients
(Fig. 3A,B). Patient fibroblasts showed reduced auxilin
(P = 0.009) and a trend for increased GAK protein
(P = 0.11; Fig. 3C). Patient CSF auxilin levels were even
more significantly reduced (P = 0.0015; Fig. 3D). Nota-
bly, CSF-GAK levels were significantly increased in
patients (P = 0.0014; Fig. 3D). CSF immunoblotting
studies showed that several key components of the
dopaminergic synapse were significantly reduced,
including tyrosine hydroxylase (TH; P = 0.0001), vesic-
ular monoamine transporter (VMAT; P = 0.0002),
dopamine transporter (DAT; P = 0.0003), and D2
receptor (D2R; P = 0.002; Fig. 3E).
Discussion
Juvenile parkinsonism attributed to DNAJC6 muta-
tions has only recently been reported. Here, we report
on a further 6 patients from three families, with two
previously unreported homozygous nonsense mutations
in DNAJC6. Moreover, our findings on 123I-FP-CIT
SPECT (DaTScan) imaging, CSF analysis, and immuno-
blotting suggest downstream dyshomeostasis of auxilin,
GAK, and dopaminergic proteins in DNAJC6-related
disease.
Our data confirms that all reported cases of juvenile-
onset DNAJC6-parkinsonism have core clinical charac-
teristics (Table 1), including (1) clinical presentation of
progressive parkinsonism toward of the first decade
(median, 10 years; range, 7–13), (2) significant neuro-
logical regression thereafter, and (3) loss of ambulation
in mid-adolescence.12-14,21 In contrast to adult-onset
PD, childhood parkinsonian disorders rarely present
with a “pure” parkinsonian phenotype, as illustrated
by the classical primary pediatric monoamine neuro-
transmitter disorders.20 Similarly, in early-onset
DNAJC6-related disease, parkinsonism is commonly
present in tandem with a multitude of other clinical fea-
tures, including dystonia, moderate learning difficulties,
epilepsy, and neuropsychiatric features12-14,21
(Table 1). Furthermore, many of our patients had evi-
dence of bulbar dysfunction, gut dysmotility, and sleep
disturbance. The majority of our patients showed lim-
ited response to L-dopa and other standard therapies
for parkinsonism-dystonia. They experienced severe,
often intolerable, side effects with dopaminergic agents,
including on-off phenomenon and severe dyskinesia,
particularly at higher drug dosages.
123I-FP-CIT SPECT (DaTScan) was performed in 3
patients, demonstrating reduced tracer uptake in the basal
ganglia, suggestive of impaired presynaptic dopamine
uptake and striatonigral neurodegeneration. Postmortem
studies have confirmed striatal dopamine deficiency in
patients with parkinsonism.22,23 Together, these observa-
tions suggest a neurodegenerative process in DNAJC6
patients. MRI brain imaging further corroborates this
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hypothesis; the mild generalized cerebral and/or cerebellar
atrophy in 4 patients suggests that DNAJC6-related disor-
ders may also be associated with neuronal loss in other
regions of the central nervous system.
All 6 cases fit the juvenile phenotype associated with
this gene, though more recently, DNAJC6 mutations
have been reported in early adult-onset PD.14 Although
there are a number of overlapping features (progressive
parkinsonism, psychiatric features), affected patients
presented later (range, 21–42 years) and seizures and
cognitive decline are not reported.
Homozygous and compound heterozygous mutations
in DNAJC6 are predicted to result in loss of protein func-
tion. To date, splice-site variants,12 large multiexonic
deletions,24 truncating mutations,13 and missense muta-
tions14 have been reported. All 6 patients in our cohort
had nonsense mutations, predicted to cause nonsense-
mediated decay or premature protein truncation. Five of
the 6 reported patients are from two consanguineous fam-
ilies originating from the same region in Pakistan, and all
have the same nonsense mutation. SNP array confirmed a
common haplotype at this disease locus for all affected
children, suggesting a possible founder effect.
DNAJC6 encodes for auxilin, a neuronally expressed
J-chaperone protein involved in the uncoating of
clathrin-coated vesicles25,26 (Fig. 4). Auxilin modifies the
three-dimensional conformation of heavy-chain clathrin
triskelions, leading to clathrin coat distortion, instability,
and subsequent disassembly.25,26 Neurotransmission
involves rapid continuous recycling of synaptic vesicles
through CME. Deficiency in auxilin ultimately results in
impairment of synaptic vesicle recycling and impaired
neurotransmission. Similarly, aberrant synaptic vesicular
trafficking is also evident in other forms of early-onset
parkinsonism, including LRRK2,27,28 VMAT2,29 and
SNCA-related disease.30 Clathrin-mediated endocytosis is
crucial for the regulation of developmental signaling path-
ways through internalization of receptors or ligands and is
required for axon and dendrite outgrowth.31 Presence of
developmental delay well before onset of parkinsonism in
patients with DNAJC6 mutations further corroborates the
notion that auxilin is likely to have a central role in neuro-
development, given its role in CME. InDrosophila, auxilin
is crucial for Notch signaling, a developmental pathway
that regulates neural stem-cell proliferation, survival,
renewal, and differentiation, as well as neuronal specifica-
tion of dopaminergic neurons.32-34
To investigate the downstream effects of DNAJC6
mutations, we studied auxilin and GAK protein levels
in 2 patients using patient fibroblasts and CSF. Auxilin
is a neuron-specific protein, enriched in presynaptic ter-
minals, whereas GAK is an ubiquituously expressed
FIG. 4. Schematic representation of DNAJC6-encoded auxilin protein function. The role of auxilin in synaptic vesicle recycling and endocytic pathway.
(A) A nascent clathrin-coated pit is formed at the presynaptic membrane, followed by membrane invagination; (B) the pit develops into a clathrin-coated
vesicle, where the clathrin lattice consists of (C) clathrin triskelions formed by three crossed ankle regions. (D) Auxilin (pale green square) binds to an
exposed domain in the heavy chain of the clathrin. (E) Auxilin facilitates a conformational change in clathrin that allows binding of Hsc70 and by
ATPase-mediated activity, and the clathrin lattice is disrupted and distorted, leading to (F) clathrin disassembly allowing subsequent delivery of cargo
neurotransmitters to the membrane or other vesicle in the endocytic pathway. Hsc70, heat shock cognate protein 70. [Color figure can be viewed at
wileyonlinelibrary.com]
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protein.35,36 Auxilin and GAK are highly homologous
proteins that both have the ability to bind clathrin and
clathrin adaptor protein 2 in order to initiate clathrin
uncoating of endocytosed vesicles.37 In the auxilin
knockout mouse model, it is reported that upregulation
of GAK can partially compensate for the loss of auxilin
and decrease mortality.35 We therefore wished to deter-
mine whether a similar compensatory mechanism was
evident in our patients. In our study, we observed that
patient fibroblast auxilin protein levels were signifi-
cantly reduced when compared to controls, as previ-
ously reported.14 We found that patient fibroblast GAK
levels were slightly, but not significantly, increased,
whereas patient CSF GAK protein levels were signifi-
cantly increased. Our findings support upregulation of
brain GAK levels in DNAJC6 patients, partially com-
pensating for auxilin reduction, as evident in the auxilin
knockout mouse model.35
Diagnostic CSF neurotransmitter analysis revealed that
levels of the stable dopamine metabolite (HVA) were
either below the age-related reference ranges or close to
the lower limit of normal in our patients, indicating
impaired dopamine turnover. Indeed, CSF-HVA levels
and HVA:5-HIAA ratios were comparable to those
observed in TH deficiency, an inherited dopamine synthe-
sis defect associated with central dopamine deficiency.20
In order to determine how DNAJC6 mutations may
impact the dopaminergic system, we used patient CSF to
analyze proteins involved in dopamine signaling and
homeostasis. We observed that patient CSF had signifi-
cantly reduced levels of VMAT, DAT, TH, andD2Rwhen
compared to controls. 123I-FP-CIT SPECT (DaTScan)
imaging additionally provides in vivo evidence of impaired
DAT function inDNAJC6 patients. VMAT and DAT are
both synaptic transporters recycled through clathrin-
mediated endocytosis.38,39 The reduction in HVA associ-
ated with low VMAT/DAT protein levels may imply that
the observed dopamine deficiency is associated with
impaired clathrin-mediated neurotransmitter recycling.
D2R is also postulated to be internalized through clathrin-
mediated endocytosis.38,39 Neurons internalize receptors
to adjust excitability and degrade, resensitize, and recycle
desensitized receptors.38,39 DNAJC6 mutations thus may
affect D2R protein levels and normal postsynaptic func-
tion. It is likely that presynaptic D2R autoreceptor func-
tion will also be affected, leading to aberrant TH
regulation.40
Overall, our findings suggest that the mechanisms
governing DNAJC6-associated parkinsonism are likely
to be multifactorial. Another plausible explanation for
the reduction in synaptic protein levels may be as a result
of neurodegeneration secondary to defective chaperone
function. Auxilin and other J-chaperone proteins play a
crucial role in regulating the folding and conformational
change of proteins tomaintain integrity in the neuron.41,42
Indeed, in the auxilin knockout mouse model, there is
sequestration of clathrin cages in the cerebellum.35 With
impaired auxilin function, a cumulative effect of seques-
teredmisfolded proteins and accumulation of clathrin coat
components in assembled coats and cages may lead to
apoptotic cascades and neurodegeneration. There is grow-
ing interest in the role of such chaperone proteins in
human disease and mutations in eight distinct J proteins
(DNAJB2, DNAJB6, DNAJC5, DNAJC6, DNAJC12,
DNAJC13, DNAJC19, and DNAJC29) have been
described.43,44 Future research into such
“chaperonopathies” may provide further insights into
neurodegenerative disorders.
In conclusion, we report on a cohort of patients with
previously unreported DNAJC6 mutations associated
with early neurodevelopmental delay, juvenile parkinson-
ism, and neurological regression in the second decade of
life. We further demonstrate disturbance of dopamine
homeostasis in patient-derived CSF and report on a possi-
ble GAK-mediated compensatory mechanism for auxilin
deficiency. Mutations in DNAJC6 are rare, but a likely
under-recognized cause of parkinsonism-dystonia in
infants and children. Elucidating the genetic diagnosis has
important implications for families given that early diag-
nosis negates the need for extensive invasive investiga-
tions, facilitates treatment strategies, and aids genetic
counseling for future pregnancies. The early clinical fea-
tures and CSF neurotransmitter signature observed in our
patients can mimic primary neurotransmitter disorders,
and DNAJC6 mutations should thus be considered as a
differential diagnosis. We observed reduced auxilin and
increased GAK protein levels, suggesting a possible com-
pensatory role for GAK in this condition. Study of CSF
synaptic proteins suggest downstream effects on dopa-
mine synthesis, recycling, homeostasis, and signaling that
may result from a combination of primary auxilin defi-
ciency and neurodegeneration. Abnormal synaptic vesicle
dynamics are increasingly recognized as a disease mecha-
nism in neurodegenerative parkinsonian disorders, and
future research into elucidating the pathogenesis of such
conditions will no doubt assist the development of novel
targeted treatments.
Acknowledgments: We thank the patients and families for their partic-
ipation in this study. We acknowledge Kerra Pearce, Mark Kristiansen,
and Alan Pittman (UCL Genomics) for assistance with the SNP arrays and
whole-exome sequencing. We thank Professor Lois Greene for kindly pro-
viding the anti-auxilin and GAK antibodies.
References
1. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene
cause autosomal recessive juvenile parkinsonism. Nature 1998;392:
605–608.
2. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-
onset Parkinson’s disease caused by mutations in PINK1. Science
2004;304:1158–1160.
Movement Disorders, Vol. 35, No. 8, 2020 1367
D N A J C 6 P A R K I N S O N I S M A N D D O P A M I N E H O M E O S T A S I S
3. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene
associated with autosomal recessive early-onset parkinsonism. Sci-
ence 2003;299:256–259.
4. Ramirez A, Heimbach A, Gründemann J, et al. Hereditary parkin-
sonism with dementia is caused by mutations in ATP13A2, encoding
a lysosomal type 5 P-type ATPase. Nat Genet 2006;38:1184–1191.
5. Paisan-Ruiz C, Bhatia KP, Li A, et al. Characterization of PLA2G6
as a locus for dystonia-parkinsonism. Ann Neurol 2009;65:19–23.
6. Fonzo AD, Dekker MCJ, Montagna P, et al. FBXO7 mutations
cause autosomal recessive, early-onset parkinsonian-pyramidal syn-
drome. Neurology 2009;72:240–245.
7. Ng J, Zhen J, Meyer E, et al. Dopamine transporter deficiency syn-
drome: phenotypic spectrum from infancy to adulthood. Brain
2014;137:1107–1119.
8. Tuschl K, Meyer E, Valdivia LE, et al. Mutations in SLC39A14 disrupt
manganese homeostasis and cause childhood-onset parkinsonism-dys-
tonia. Nat Commun 2016;7:11601.
9. Schneider SA, Bhatia KP, Hardy J. Complicated recessive dystonia
parkinsonism syndromes. Mov Disord 2009;24:490–499.
10. Bonifati V. Genetics of Parkinson’s disease—state of the art, 2013.
Parkinsonism Relat Disord 2014;20(Suppl. 1):S23–S28.
11. Quadri M, Fang MY, Picillo M, et al. Mutation in the SYNJ1 gene
associated with autosomal recessive, early-onset parkinsonism. Hum
Mutat 2013;34:1208–1215.
12. Edvardson S, Cinnamon Y, Ta-Shma A, et al. A deleterious muta-
tion in DNAJC6 encoding the neuronal-specific clathrin-uncoating
co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS
One 2012;7:e36458.
13. Koroglu C, Baysal L, Cetinkaya M, Karasoy H, Tolun A. DNAJC6
is responsible for juvenile parkinsonism with phenotypic variability.
Parkinsonism Related Disord 2013;19:320–324.
14. Olgiati S, Quadri M, Fang MY, et al. DNAJC6 mutations associated
with early-onset Parkinson’s disease. Ann Neurol 2016;79:244–256.
15. Hyland K, Surtees RA, Heales SJ, Bowron A, Howells DW, Smith I.
Cerebrospinal fluid concentrations of pterins and metabolites of
serotonin and dopamine in a pediatric reference population. Pediatr
Res 1993;34:10–14.
16. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for com-
paring genomic features. Bioinformatics 2010;26:841–842.
17. Meyer E, Carss KJ, Rankin J, et al. Mutations in the histone methyl-
transferase gene KMT2B cause complex early-onset dystonia. Nat
Genet 2017;49:223–237.
18. Consortium UK, Walter K, Min JL, et al. The UK10K project iden-
tifies rare variants in health and disease. Nature 2015;526:82–90.
19. Ortez C, Duarte ST, Ormazábal A, et al. Cerebrospinal fluid synap-
tic proteins as useful biomarkers in tyrosine hydroxylase deficiency.
Mol Genet Metab 2015;114:34–40.
20. Willemsen MA, Verbeek MM, Kamsteeg EJ, et al. Tyrosine hydrox-
ylase deficiency: a treatable disorder of brain catecholamine biosyn-
thesis. Brain 2010;133:1810–1822.
21. Elsayed LE, Drouet V, Usenko T, et al. A novel nonsense mutation
in DNAJC6 expands the phenotype of autosomal-recessive juvenile-
onset Parkinson’s disease. Ann Neurol 2016;79:335–337.
22. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson
disease and the neurobiology of axons. Ann Neurol 2010;67:
715–725.
23. Burke RE, O’Malley K. Axon degeneration in Parkinson’s disease.
Exp Neurol 2013;246:72–83.
24. Vauthier V, Jaillard S, Journel H, Dubourg C, Jockers R, Dam J.
Homozygous deletion of an 80 kb region comprising part of
DNAJC6 and LEPR genes on chromosome 1P31.3 is associated with
early onset obesity, mental retardation and epilepsy. Mol Genet
Metab 2012;106:345–350.
25. Ungewickell E, Ungewickell H, Holstein SEH, et al. Role of auxilin
in uncoating clathrin-coated vesicles. Nature 1995;378:632–635.
26. Eisenberg E, Greene LE. Multiple roles of auxilin and Hsc70 in
clathrin-mediated endocytosis. Traffic 2007;8:640–646.
27. Migheli R, Del Giudice MG, Spissu Y, et al. LRRK2 affects vesicle
trafficking, neurotransmitter extracellular level and membrane recep-
tor localization. PLoS One 2013;8:e77198.
28. Xiong Y, Dawson Valina L, Dawson Ted M. LRRK2 GTPase dys-
function in the pathogenesis of Parkinson’s disease. Biochem Soc
Trans 2012;40:1074–1079.
29. Rilstone JJ, Alkhater RA, Minassian BA. Brain dopamine-serotonin
vesicular transport disease and its treatment. N Engl J Med 2013;
368:543–550.
30. Alter SP, Lenzi GM, Bernstein AI, Miller GW. Vesicular integrity in
Parkinson’s disease. Curr Neurol Neurosci Rep 2013;13:362–362.
31. Yap CC, Winckler B. Adapting for endocytosis: roles for endocytic
sorting adaptors in directing neural development. Front Cell Neu-
rosci 2015;9:119.
32. Eun SH, Banks SML, Fischer JA. Auxilin is essential for delta signal-
ing. Development 2008;135:1089–1095.
33. Lathia JD, Mattson MP, Cheng A. Notch: from neural development
to neurological disorders. J Neurochem 2008;107:1471–1481.
34. Tio M, Toh J, Fang W, Blanco J, Udolph G. Asymmetric cell divi-
sion and Notch signaling specify dopaminergic neurons in Drosoph-
ila. PLoS One 2011;6:e26879.
35. Yim YI, Sun T, Wu LG, et al. Endocytosis and clathrin-uncoating
defects at synapses of auxilin knockout mice. Proc Natl Acad Sci U
S A 2010;107:4412–4417.
36. Ahle S, Ungewickell E. Auxilin, a newly identified clathrin-associated
protein in coated vesicles from bovine brain. J Cell Biol 1990;111:19–29.
37. Scheele U, Kalthoff C, Ungewickell E. Multiple interactions of
auxilin 1 with clathrin and the AP-2 adaptor complex. J Biol Chem
2001;276:36131–36138.
38. Ferguson SSG, Caron MG. G protein-coupled receptor adaptation
mechanisms. Semin Cell Dev Biol 1998;9:119–127.
39. Sorkin A, Von Zastrow M. Signal transduction and endocytosis: close
encounters of many kinds. Nat Rev Mol Cell Biol 2002;3:600–614.
40. Blackstone C. Infantile parkinsonism-dystonia: a dopamine “trans-
portopathy”. J Clin Invest 2009;119:1455–1458.
41. Kakkar V, Prins LCB, Kampinga HH. DNAJ proteins and protein
aggregation diseases. Curr Top Med Chem 2012;12:2479–2490.
42. Kampinga HH, Craig EA. The HSP70 chaperone machinery: J pro-
teins as drivers of functional specificity. Nat Rev Mol Cell Biol
2010;11:579–592.
43. Koutras C, Braun JEA. J protein mutations and resulting
proteostasis collapse. Front Cell Neurosci 2014;8:191.
44. Anikster Y, Haack TB, Vilboux T, et al. Biallelic mutations in
DNAJC12 cause hyperphenylalaninemia, dystonia, and intellectual
disability. Am J Hum Genet 2017;100:257–266.
Supporting Data
Additional Supporting Information may be found in
the online version of this article at the publisher’s
web-site.
1368 Movement Disorders, Vol. 35, No. 8, 2020
N G E T A L
